Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- SystImmune Inc.
- Study ID
- NCT06293898
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Biliary Tract Cancer
- Breast Cancer
- Cervical Cancer
- Endometrial Cancer
- Esophageal Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Lung Cancer
- Ovarian Cancer
- Urothelial Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- BL-M07D1 — DRUGDrug: BL-M07D1 The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. BL-M17D1 will be administered on Day 1 by intravenous infusion every 3 weeks. Other Names: BL-M07D1
Study Details
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Key Dates
- Start date
- Feb 9, 2024
- Status verified
- Mar 2026
- Primary completion
- Dec 15, 2028
- Completion
- Apr 15, 2029
Study Design
- Enrollment
- 280 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Experimental: Dose EscalationBeginning with Cycle 1, BL-M07D1 will be administered on Day 1 by (IV) infusion every 3 weeks (D1Q3W)
- Experimental: Experimental: Dose FindingBeginning with Cycle 1, BL-M07D1 will be administered on Day 1 by (IV) infusion every 3 weeks (D1Q3W)
- Experimental: Experimental: Dose ExpansionBeginning with Cycle 1, BL-M07D1 will be administered on Day 1 by (IV) infusion every 3 weeks (D1Q3W)
Primary Outcome Measure
Summary of safety [ Time Frame: Though study completion, an average of 24 months ]
Central Contacts
- Christine LaRock425-453-6841
- Whitney Eakins425-453-6841
Locations (17)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Alabama Birmingham | Birmingham | Alabama | 35294 | Nusrat Jahan, MD (PRINCIPAL_INVESTIGATOR) |
| City of Hope | Duarte | California | 91010 | Abheshik Tripathi, MD (PRINCIPAL_INVESTIGATOR) |
| Cedars Sinai | Los Angeles | California | 90211 | Jin Sun Bitar, MD (PRINCIPAL_INVESTIGATOR) |
| Scripps Health | San Diego | California | 92121 | Jackie Dexter Wesleigh Edwards, MD (PRINCIPAL_INVESTIGATOR) |
| University of Miami | Miami | Florida | 33136 | Gilberto Lopes, MD (PRINCIPAL_INVESTIGATOR) |
| Sarah Cannon Research institute - Lake Nona Florida | Orlando | Florida | 32827 | Cesar Perez Batista, MD (PRINCIPAL_INVESTIGATOR) |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | Donna Wheatley Sharad Ghamande, MD (PRINCIPAL_INVESTIGATOR) |
| University of Chicago Medicine | Chicago | Illinois | 60637 | Gini Fleming, MD (PRINCIPAL_INVESTIGATOR) |
| University of Illinois Cancer Center | Chicago | Illinois | 60612 | Oana Danciu, MD (PRINCIPAL_INVESTIGATOR) |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Joyce Liu, MD (PRINCIPAL_INVESTIGATOR) |
| Karmanos Cancer Institiute | Detroit | Michigan | 48201 | Wasif Saif, MD (PRINCIPAL_INVESTIGATOR) |
| NYU Langone Hospital - Long Island Investigational Pharmacy | Mineola | New York | 11501 | Nancy Chan, MD (PRINCIPAL_INVESTIGATOR) |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York | 10016 | Nancy Chan, MD (PRINCIPAL_INVESTIGATOR) |
| Providence Portland Medical Center | Portland | Oregon | 97213 | Anthony Sylvester Rachel Sanborn, MD (PRINCIPAL_INVESTIGATOR) |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | Erica Hamilton, MD (PRINCIPAL_INVESTIGATOR) |
| Oncology Consultants | Houston | Texas | 77030 | Laura Guerra 7136000913 Julio Peguero, MD (PRINCIPAL_INVESTIGATOR) |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | Alexander Spira, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Birmingham, AL
By condition
By specialty
Related Studies
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruiting · Northwestern University · Chicago, Illinois
- Lung Cancer Biomarkers and ScreeningRecruiting · NYU Langone Health · New York, New York
- DNA Analysis of Blood and Tissue from Patients with Lung CancerRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenRecruiting · M.D. Anderson Cancer Center · Miami, Florida